A coalition of 30 state treasurers, pension funds, and faith-based groups are filing shareholder proposals asking 10 drug makers and distributors to investigate how these companies are responding to the increased business risks caused by the opioid crisis.
In announcing their plans, the coalition noted that drug makers are coming under increasing “legal and legislative scrutiny” for allegedly failing to disclose the addictive potential of opioid painkillers, and that distributors are being pressured to do a better job of reporting suspicious orders to state and federal authorities.
“We have witnessed, firsthand, the ravages of opioid misuse in the communities in which we serve and believe corporations must play an important role in responding to this crisis. Improved oversight and risk management structures to prevent opioid misuse are an essential first step in this response,” said Donna Meyer of Mercy Investment Services, the asset manager for the Sisters of Mercy, in a statement.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect